Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

Pfizer may not be able to recover the $75.2 million that was left from a Securities and Exchange Commission insider trading ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...